Our researchers’ achievements

1,600 achievements

Sharing findings and discoveries is essential for the advancement of science. If research results are valid and reliable, they are published in journals read by the members of the international scientific community, so that everyone can learn from and build on these achievements.

In 2016, our researchers published more than 1,600 scientific papers, confirming the validity recognized by the international community and the wisdom of our funding decisions, with important ramifications for patients.

Our researchers have published their results in some of the most respected, authoritative and selective scientific journals.

Some of the most important studies are announced to the general public through our institutional channels and with collaboration from the media, so that all who support us can learn how their help has paid off.

Below is a sample of the most significant results published in 2016 by our researchers.

Metastatic prostate cancer: new drug resistance mechanism discovered
Published in: Nature Medicine
IF: 28,22
Authors: Francesca Demichelis et al., University of Trento

The authors reconstructed the molecular behavior that turns some aggressive forms of prostate cancer into drug-resistant neuroendocrine tumors. This paves the way for the study of new treatment targets. read more (in Italian) ›

Biological drugs and the immune system team up against colorectal cancer
Published in: Nature Medicine
IF: 28,22
Authors: Maria Rescigno et al., Istituto di Oncologia, Milan

Some pharmaceuticals, like cetuximab, do more than kill tumor cells. They make them “visible” to the immune system, which can therefore respond by eliminating the malignant cells not killed by the drug. read more (in Italian) ›

A molecular signature to predict the course of ovarian cancer
Published in: The Lancet Oncology
IF: 24,69
Authors: Delia Mezzanzanica et al., Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

MiROvaR, by analyzing a specific group of microRNAs, can quantify the risk that patients with ovarian cancer will relapse after standard treatment. read more (in Italian) ›

A promising new colon cancer treatment
Published in: The Lancet Oncology
IF: 24,69
Authors: Salvatore Siena, Silvia Marsoni et al., Ospedale Niguarda (Milan) and Istituto IRCCS di Candiolo (Turin)

Project Heracles, a joint effort by the Istituto di Candiolo and Niguarda Hospital, funded by AIRC using “taxpayer’s choice” contributions, has led to a promising new treatment for certain forms of colon cancer. read more (in Italian) ›

Giving immunotherapy the upper hand
Published in: Cancer Cell
IF: 23,52
Authors: Vincenzo Bronte et al., University of Verona

Thanks to our immune system we have natural weapons against cancer, such as cytotoxic T lymphocytes, which eliminate tumor cells. The problem is that the tumor knows how to defend itself against these natural killers. Vincenzo Bronte’s research team has identified new molecular mechanisms that could be used to help cancer-fighting T lymphocytes win the battle. read more (in Italian) ›

Rituximab: still surprising after all these years
Published in: Journal of Clinical Oncology
IF: 20,9
Authors: Alessandro Rambaldi et al., ASST Papa Giovanni XXIII, Bergamo

This study showed that in the most advanced forms of diffuse large B-cell lymphoma, combining Rituximab with conventional outpatient chemotherapy is just as effective as combining it with high-dose chemotherapy with autologous hematopoietic stem cell transplantation. Nearly 20 years since its first use, this drug continues to optimize the effectiveness of treatments and reduce their toxicity. read more ›

A new tumor-fighting strategy: target proteasome and mutant p53 protein
Published in: Nature Cell Biology
IF: 19,67
Authors: Giannino Del Sal et al., LNCIB and University of Trieste

A cocktail of drugs that target the protein disposal system and agents that inactivate mutant p53 protein: this combination combats treatment resistance and helps stop tumors from growing. The discovery comes from a team of researchers and clinical oncologists funded by AIRC and coordinated by the Laboratorio Nazionale CIB and the University of Trieste. read more ›

Studying the cancer genome predicts transplant success in acute and chronic leukemias
Published in: Journal of Clinical Oncology
IF: 18,44
Authors: Matteo Giovanni Della Porta et al., Fondazione Humanitas per la Ricerca, Rozzano (Milan)

In recent years, advanced technologies for studying the genome have made it possible to investigate the biological mechanisms of many blood diseases. The Gruppo Italiano per il Trapianto di Midollo Osseo has published the first study demonstrating that analysis of the cancer genome (obtained from blood cells) can predict transplant success in myelodysplastic syndromes and acute leukemias. The project lays the groundwork for personalized treatment programs in acute and chronic leukemias, in which diagnosis and choice of treatment depend not on clinical aspects but on the gene mutations in each patient’s blood cells. read more ›

Thyroid hormones regulate the formation and growth of basal cell carcinomas
Published in: Journal of Clinical Investigation
IF: 13,26
Authors: Monica Dentice et al., Federico II University, Naples

Basal cell carcinoma (BCC) is the most common form of cancer in humans. Like all tumors, it is caused by genetic mutations, often through overexposure to UV rays. Monica Dentice and her team have long studied the effect on skin cancers of thyroid hormones and the enzymes that regulate them, and have found a new molecular axis that might be a suitable treatment target to prevent these tumors from growing. read more ›

Liver cancer: new mechanism discovered for resistance to sorafenib
Published in: Hepatology
IF: 11,05
Authors: Gianluigi Giannelli et al., University of Bari

Sorafenib is currently the only biological drug approved for the primary liver cancer hepatocellular carcinoma. It is used in the most serious cases and acts by causing the apoptosis (suicide) of the tumor cells. Unfortunately, after a few months, many patients become resistant to treatment. Researchers In Bari have described how laminin-332—a protein of the extracellular matrix—protects the tumor from the drug, which could have important implications for treatment. read more (in Italian) ›